EHA 2025: Prof. Jesús San Miguel Receives Lifetime Achievement Award

At the 2025 Annual Congress of the European Hematology Association (EHA), Professor Jesús San Miguel was honored with the prestigious EHA Lifetime Achievement Award in recognition of his extraordinary contributions to the field of hematology, particularly in the area of multiple myeloma. This distinction represents the highest recognition granted by EHA, celebrating a career marked by scientific excellence, innovation, and lasting impact on clinical practice.

Founded in 1992, the European Hematology Association is the leading professional organization for hematologists in Europe. EHA is dedicated to promoting excellence in patient care, research, and education in hematology. Through its scientific congresses, educational programs, advocacy efforts, and international collaborations, EHA plays a pivotal role in shaping the future of hematology worldwide. The Annual EHA Congress is the association’s flagship event, bringing together clinicians, researchers, and healthcare professionals from around the world to share the latest advances in hematologic science and care.

Professor Jesús San Miguel is widely regarded as one of the most influential figures in modern hematology. He has devoted his career to advancing the diagnosis, treatment, and understanding of hematologic malignancies, with a primary focus on plasma cell disorders. After earning his medical degree from the University of Navarra and completing his PhD at the University of Salamanca, Professor San Miguel held numerous leadership positions, including Head of the Hematology Department at the University Hospital of Salamanca and, more recently, Director of Clinical and Translational Medicine at Clínica Universidad de Navarra.

His research has significantly shaped the field of multiple myeloma, contributing to the development of innovative diagnostic tools, risk stratification models, and therapeutic strategies. Professor San Miguel played a critical role in introducing and validating minimal residual disease (MRD) as a key prognostic marker in myeloma. His work has also led to the incorporation of novel agents—including proteasome inhibitors and immunomodulatory drugs—into clinical practice, dramatically improving survival outcomes and quality of life for patients.

Here are just a few of the many congratulatory posts for Dr. San Miguel shared on X

María José Calasanz:

“Amazing!!! lifetime achievement award to Jesús San Miguel”

Vincent Rajkumar:

“My advance congratulations to Dr. Jesus San Miguel who will receive the European Hematology Association. Lifetime Achievement Award Tomorrow at EHA 2025. Dr. SanMiguel has made incredible contributions to the field. A close friend and mentor to me. I’m sorry to miss the ceremony.”

Bruno Paiva:

“EHA2025 lifetime achievement award to Jesús San Miguel; my boss, mentor, friend, wedding planner and second-father! 18 years ago I was blessed by start working under his leadership, and I’m looking forward to the next 18 years!”

In addition to his scientific accomplishments, Professor San Miguel is widely respected for his leadership in academic medicine and his commitment to mentorship. He has authored or co-authored over 900 scientific publications and served on the editorial boards of several leading journals. He has also held prominent roles within EHA, including serving as a Board Councillor and Chair of the Scientific Committee, and has contributed to numerous international initiatives aimed at advancing hematology research and care.

Find more posts featuring EHA 2025 on OncoDaily.

Written by Nare Hovhannisyan, MD